本帖最后由 老马 于 2013-3-13 13:43 编辑 ' @( E m! \0 e1 ^. g
/ ^9 T v+ z* k% L) t$ o6 ~! N
健择（吉西他滨）+顺铂+阿瓦斯汀
1 S! z! ?* T' _# _! G8 b Gemzar +Cisplatin + Avastin
! e. p9 L6 O& y# O( I+ Y8 h8 k1 D/ thttp://annonc.oxfordjournals.org/content/21/9/1804.full
/ o& \+ j& E- w1 f2 W NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 i* Q o# U8 C6 |0 l+ w
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. ~' P5 H; ]7 Q# H% Q$ Z; pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # A* p- N- c# B$ ~' G) L9 |- k
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 610)
( ?' ?" k2 r3 z5 r: S+ K1 F% r; n华为网盘附件：
5 h7 o9 x- R6 i9 X* R7 D3 i【华为网盘】ava.JPG
2 `+ i- Y3 r5 D: {" | |
显身卡
